Personalis (NASDAQ:PSNL) Given “Buy” Rating at Needham & Company LLC

Personalis (NASDAQ:PSNL)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $7.25 price target on the stock. Needham & Company LLC’s price target points to a potential upside of 21.24% from the company’s current price.

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Personalis in a research note on Wednesday.

Personalis Price Performance

Shares of PSNL stock opened at $5.98 on Wednesday. The company has a market capitalization of $422.48 million, a price-to-earnings ratio of -3.56 and a beta of 1.75. The company’s fifty day moving average price is $4.68 and its 200-day moving average price is $4.31. Personalis has a one year low of $1.12 and a one year high of $7.20.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.31). The business had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. During the same quarter in the previous year, the firm earned ($0.51) earnings per share. Equities research analysts expect that Personalis will post -1.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

Large investors have recently made changes to their positions in the company. Acadian Asset Management LLC grew its holdings in Personalis by 6.7% during the 2nd quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company’s stock valued at $1,237,000 after buying an additional 66,128 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in Personalis by 42.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after purchasing an additional 4,504 shares in the last quarter. nVerses Capital LLC bought a new position in Personalis during the third quarter valued at $40,000. International Assets Investment Management LLC grew its stake in shares of Personalis by 438.0% in the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock worth $113,000 after buying an additional 17,082 shares in the last quarter. Finally, Semanteon Capital Management LP bought a new stake in shares of Personalis in the 3rd quarter worth about $375,000. 61.91% of the stock is owned by institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.